Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Income towards Parent Company: 2016-2025

Historic Income towards Parent Company for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to -$33.3 million.

  • UroGen Pharma's Income towards Parent Company fell 40.87% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.6 million, marking a year-over-year decrease of 42.70%. This contributed to the annual value of -$126.9 million for FY2024, which is 24.09% down from last year.
  • Per UroGen Pharma's latest filing, its Income towards Parent Company stood at -$33.3 million for Q3 2025, which was up 33.23% from -$49.9 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Income towards Parent Company peaked at -$21.9 million during Q3 2023, and registered a low of -$49.9 million during Q2 2025.
  • Its 3-year average for Income towards Parent Company is -$32.4 million, with a median of -$32.3 million in 2024.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first soared by 30.62% in 2021, then tumbled by 49.51% in 2025.
  • UroGen Pharma's Income towards Parent Company (Quarterly) stood at -$28.5 million in 2021, then dropped by 1.47% to -$28.9 million in 2022, then rose by 9.88% to -$26.0 million in 2023, then crashed by 44.19% to -$37.5 million in 2024, then crashed by 40.87% to -$33.3 million in 2025.
  • Its Income towards Parent Company stands at -$33.3 million for Q3 2025, versus -$49.9 million for Q2 2025 and -$43.8 million for Q1 2025.